Old Web
English
Sign In
Acemap
>
authorDetail
>
Eric Zafarana
Eric Zafarana
Bayer HealthCare Pharmaceuticals
Sorafenib
Melanoma
Medicine
Biopsy
Dacarbazine
4
Papers
149
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Sorafenib (S) and dacarbazine (D) combination in patients (pts) with advanced malignant solid tumors: Phase I study with tumor biopsy genomic analysis and dynamic contrast enhanced ultrasonography (DCE-US)
2016
Journal of Clinical Oncology
Jeannette Soria
Vladimir Lazar
N. Lassau
C. Pena
Christophe Massard
C. Robert
Serge Koscielny
Eric Deutsch
Eric Zafarana
Jean-Pierre Armand
Show All
Source
Cite
Save
Citations (10)
Pharmacokinetic results of a phase I trial of sorafenib (S) in combination with dacarbazine (DTIC) in patients with advanced metastatic melanoma or other solid tumors
2007
Journal of Clinical Oncology
Erich Brendel
Eric Zafarana
C. Figuerola
M. Ludwig
Chetan Lathia
K. Burk
Caroline Robert
J.C. Soria
Jean-Pierre Armand
Show All
Source
Cite
Save
Citations (1)
Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
2007
Clinical Cancer Research
Bernard Escudier
N. Lassau
Eric Angevin
Jean-Charles Soria
L. Chami
M. Lamuraglia
Eric Zafarana
Veronique Landreau
Brian S. Schwartz
Eric Brendel
Jean-Pierre Armand
Caroline Robert
Show All
Source
Cite
Save
Citations (138)
Gene expression profiling of sequential tumor biopsies is a powerful approach to identify putative biomarkers of therapeutic benefit in a phase I study combining sorafenib and dacarbazine
2007
Molecular Cancer Therapeutics
Vladimir Lazar
Philippe Dessen
Serge Koscielny
Ludovic Lacroix
C. Pena
Christophe Massard
Caroline Robert
Yohan Loriot
Eric Deutsch
Eric Zafarana
Jean-Charles Soria
Jean-Pierre Armand
Show All
Source
Cite
Save
Citations (0)
1